MX2025015193A - Derivados policiclicos que contienen dihidropirimidina-2,4(1h,3h)-diona y sus composiciones farmaceuticas, metodos de preparacion y usos - Google Patents

Derivados policiclicos que contienen dihidropirimidina-2,4(1h,3h)-diona y sus composiciones farmaceuticas, metodos de preparacion y usos

Info

Publication number
MX2025015193A
MX2025015193A MX2025015193A MX2025015193A MX2025015193A MX 2025015193 A MX2025015193 A MX 2025015193A MX 2025015193 A MX2025015193 A MX 2025015193A MX 2025015193 A MX2025015193 A MX 2025015193A MX 2025015193 A MX2025015193 A MX 2025015193A
Authority
MX
Mexico
Prior art keywords
dihydropyrimidine
dione
preparation
containing polycyclic
pharmaceutical composition
Prior art date
Application number
MX2025015193A
Other languages
English (en)
Spanish (es)
Inventor
Liqiang Fu
Zude Qi
Xuemei Jin
Adrian Contreras
Chin- Chun Lu
Yifeng Xia
Gang Lu
Original Assignee
Linkcure Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Linkcure Therapeutics filed Critical Linkcure Therapeutics
Publication of MX2025015193A publication Critical patent/MX2025015193A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2025015193A 2023-06-15 2025-12-15 Derivados policiclicos que contienen dihidropirimidina-2,4(1h,3h)-diona y sus composiciones farmaceuticas, metodos de preparacion y usos MX2025015193A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2023100520 2023-06-15
PCT/CN2024/099076 WO2024255810A1 (fr) 2023-06-15 2024-06-13 Dérivés polycycliques contenant de la dihydropyrimidine-2, 4 (1h, 3h)-dione et composition pharmaceutique associée, leur procédé de préparation et leur utilisation

Publications (1)

Publication Number Publication Date
MX2025015193A true MX2025015193A (es) 2026-02-03

Family

ID=93851373

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2025015193A MX2025015193A (es) 2023-06-15 2025-12-15 Derivados policiclicos que contienen dihidropirimidina-2,4(1h,3h)-diona y sus composiciones farmaceuticas, metodos de preparacion y usos

Country Status (7)

Country Link
EP (1) EP4727940A1 (fr)
KR (1) KR20260022448A (fr)
CN (1) CN121794269A (fr)
AU (1) AU2024302642A1 (fr)
IL (1) IL325349A (fr)
MX (1) MX2025015193A (fr)
WO (2) WO2024255810A1 (fr)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021053555A1 (fr) * 2019-09-16 2021-03-25 Novartis Ag Agents de dégradation de colle et leurs procédés d'utilisation
PH12022551482A1 (en) * 2019-12-18 2023-11-29 Novartis Ag 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CN116940571A (zh) * 2021-03-15 2023-10-24 诺华股份有限公司 苯并异噁唑衍生物及其用途
PY2217419A (es) * 2021-03-15 2022-09-27 Novartis Ag Derivados de pirazolopiridina y sus usos
CN116802182A (zh) * 2021-03-15 2023-09-22 诺华股份有限公司 吡唑并吡啶衍生物及其用途
WO2022195355A1 (fr) * 2021-03-15 2022-09-22 Novartis Ag Dérivés de benzisoxazole et leurs utilisations
CN117203216A (zh) * 2021-06-25 2023-12-08 和径医药科技(上海)有限公司 蛋白抑制剂或降解剂、包含其的药物组合物及医药上的用途
US20240368121A1 (en) * 2021-08-20 2024-11-07 Biotheryx, Inc. Estrogen receptor degraders, pharmaceutical compositions thereof, and their therapeutic applications

Also Published As

Publication number Publication date
EP4727940A1 (fr) 2026-04-22
CN121794269A (zh) 2026-04-03
AU2024302642A1 (en) 2026-02-05
WO2025256460A1 (fr) 2025-12-18
KR20260022448A (ko) 2026-02-19
WO2024255810A1 (fr) 2024-12-19
IL325349A (en) 2026-02-01

Similar Documents

Publication Publication Date Title
JOP20220152A1 (ar) مشتقات 3-(5- ميثوكسي -1- أوكسو أيزو إندولين -2- يل) بيبريدين -2، 6- دايون واستخداماتها
ZA202403388B (en) Small molecules for treatement of cancer
JOP20220179A1 (ar) N4-هيدروكسي سيتيدين ومشتقات واستخدامات مضادة للفيروسات مرتبطة بها
PH12022550611A1 (en) Brd9 bifunctional degraders and their methods of use
EA200600076A1 (ru) Композиции и способы увеличения активности теломеразы
EP4442241A3 (fr) Remplacement du rétinol dans le traitement de la peau
UA86614C2 (ru) Соединение, которое имеет активность ингибитора киназ, фармацевтическая композиция, которая включает указанное соединение, и их применение для приготовления лекарственного препарата
BRPI0517567A (pt) composto ou um sal, solvato, ou derivado fisiologicamente funcional farmaceuticamente aceitável do mesmo, composição farmacêutica, usos de um composto ou um sal, solvato, ou derivado fisiologicamente funcional farmaceuticamente aceitável do mesmo e de uma composição farmacêutica, e, processo para preparar um composto
ZA202211464B (en) Tetrahydroisoquinoline compounds as nrf2 activators
ZA202307290B (en) Pyrazolopyridine derivatives and uses thereof
MY207469A (en) Therapeutic compounds
MA53427B1 (fr) Inhibiteurs de l'arginase et leurs méthodes d'utilisation
ZA202211465B (en) Tetrahydroisoquinoline compounds as nrf2 activators
WO2025019819A3 (fr) Agents de dégradation de protéine à petites molécules de mutant de kras g12d
MX2022012001A (es) Tratamiento preventivo de la migra?a.
ATE192923T1 (de) Verwendung von boswelliasäure zur behandlung von hirntumoren
PH12021552133A1 (en) Aromatic derivatives, preparation methods, and medical uses thereof
MX2025015193A (es) Derivados policiclicos que contienen dihidropirimidina-2,4(1h,3h)-diona y sus composiciones farmaceuticas, metodos de preparacion y usos
MX2025005154A (es) Formulaciones orales compactables de ibutamoren.
PH12020551493A1 (en) Triazacyclododecansulfonamide (``tcd``)-based protein secretion inhibitors
WO2024231881A3 (fr) Formes polymorphes et formulations de leriglitazone
WO2024073328A3 (fr) Procédés de traitement du cancer et compositions associées
IL154775A0 (en) 21-hydroxy-6, 19-oxidoprogesterone (21oh-6, 19op) analogues, their preparation and use
WO2022104088A3 (fr) Méthode de traitement d'une maladie amyloïdogénique
MX2025010543A (es) Composiciones que comprenden 5-metoxi-2-aminoindan para el tratamiento de la depresion